BRCA1 and BRCA2 gene mutations and risk of breast cancer: Public health perspectives

American Journal of Preventive Medicine

Volumn 16, Issue 2, 1999, Pages 91-98

  Coughlin, Steven S ^a   Khoury, Muin J ^b   Steinberg, Karen K ^b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

BRCA1; Breast cancer; Cancer genetics; Genetic testing; Germline mutation; Ovarian cancer; Screening

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOMAL LOCALIZATION; CHROMOSOME 17; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; POPULATION RESEARCH; REVIEW;

EID: 0032992092     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(98)00136-6     Document Type: Article

References (64)

1. Hall J.M., Lee M.K., Newman B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250:1990;1684-1689.
2. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
3. Wooster R., Neuhausen S.L., Mangion J., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 265:1994;2088-2090.
4. JAMA. 271:1994;785.
5. Hubbard R., Lewontin R.C. Pitfalls of genetic testing. N Engl J Med. 334:1996;1192-1194.
6. Khoury M.J. From genes to public health the applications of genetic technology in disease prevention . Am J Public Health. 86:1996;1717-1722.
7. Shattuck-Eidens D., McClure M., Simard J., et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA. 273:1995;535-541.
8. Szabo C.I., King M.C. Population genetics of BRCA1 and BRCA2 (editorial). Am J Hum Genet. 60:1997;1013-1020.
9. Levylahad E., Catane R., Eisenberg S., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel-frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 60:1997;1059-1067.
10. Collins F.S. BRCA1-lots of mutations, lots of dilemmas. N Engl J Med. 334:1996;186-188.
11. Grompe M. The rapid detection of unknown mutations in nucleic acids. Nature Genetics. 5:1993;111-117.
12. Shattuck-Eidens D., Oliphant A., McClure M., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 278:1997;1242-1250.
13. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1997;1401-1408.
14. Whittemore A.S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 60:1997;496-504.
15. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
16. Ford D., Easton D.F., Bishop D.T., et al. Risks of cancer in BRCA1-mutation carriers. Lancet. 343:1994;692-695.
17. Szabo C.I., King M.C. Inherited breast and ovarian cancer. Hum Molec Genet. 4:1995;1811-1817.
18. Burke W., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA. 277:1997;997-1003.
19. Cancer Facts and Figures, 1998. 1998;American Cancer Society, Inc, New York.
20. Mettlin C., Croghan I., Natarajan N., et al. The association of age and familial risk in a case-control study of breast cancer. Am J Epidemiol. 131:1990;973-983.
21. Newman B., Millikan R.C., King M.-C. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 19:1997;69-79.
22. Bain C., Speizer F.E., Rosner B., et al. Family history of breast cancer as a risk indicator for the disease. Am J Epidemiol. 111:1980;301-308.
23. Andersen T.I. Genetic heterogeneity in breast cancer susceptibility. Acta Oncol. 35:1996;407-410.
24. Weber B.L. Familial breast cancer. Recent Results Cancer Res. 140:1996;5-16.
25. Xu C.F., Solomon E. Mutations of the BRCA1 gene in human cancer. Sem in Cancer Biol. 7:1996;33-40.
26. Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 57:1995;1457-1462.
27. Bieche I., Lidereau R. Genetic alterations in breast cancer. Genes Chromosom Cancer. 14:1995;227-251.
28. Radford D.M., Zehnbauer B.A. Inherited breast cancer. Surg Clin North Am. 76:1996;205-220.
29. Swift M., Reitnauer P.J., Morrell D., et al. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 316:1987;1289-1294.
30. Helzlsouer K.J., Selmin O., Huang H.-Y., et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst. 90:1998;512-518.
31. Kelsey K.T., Hankinson S.E., Colditz G.A., et al. Glutathione S-transferase class μ deletion polymorphism and breast cancer results from prevalent versus incident cases . Cancer Epidemiol Biomark Prev. 6:1997;511-515.
32. Kelsey K.T., Wiencke J.K. Growing pains for the environmental genetics of breast cancer observations on a study of the glutathione S-transferases . J Natl Cancer Inst. 90:1998;484-485.
33. Ambrosone C.B., Freudenheim J.L., Graham S., et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 276:1996;1494-1501.
34. Feigelson H.S., Coetzee G.A., Kolonel L.N., et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57:1997;1063-1065.
35. Struewing J.P., Abeliovich D., Peretz T., et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals (letter). Nature Genetics. 11:1995;198-200.
36. Langston A.A., Malone K.E., Thompson J.D., et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 334:1996;137-142.
37. Takahashi H., Chiu H.C., Bandera C.A., et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 56:1996;2738-2741.
38. Struewing J.P., Brody L.C., Erdos M.R., et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet. 57:1995;1-7.
39. Tonin P., Serova O., Lenoir G., et al. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet. 57:1995;189.
40. Goldgar D.E., Reilly P.R. A common BRCA1 mutation in the Ashkenazim. Nat Genet. 11:1995;113-114.
41. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 14:1996;185-187.
42. Oddoux C., Struewing J.P., Clayton C.M., et al. The carrier frequency of BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 14:1996;188-190.
43. Abeliovich D., Kaduri L., Lerer I., et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 60:1997;505-514.
44. Levy-Lahad E., Catane R., Eisenberg S., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families . Am J Hum Genet. 60:1997;1059-1067.
45. FitzGerald M.G., MacDonald D.J., Krainer M., et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 334:1996;143-149.
46. Struewing J.P., Tarone R.E., Brody L.C., et al. BRCA1 mutations in young women with breast cancer (letter). Lancet. 347:1996;1493.
47. Malone K.E., Daling J.R., Thompson J.D., et al. BRCA1 mutations and breast cancer in the general population. Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 279:1998;922-929.
48. Eeles R. Testing for the breast cancer predisposition gene, BRCA1. BMJ. 313:1996;572.
49. Newman B., Mu H., Butler L.M., et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 279:1998;915-921.
50. Slattery M.L., Kerber R.A. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA. 270:1993;1563-1568.
51. Weber B.L., Giusti R.M., Liu E.T. Developing strategies for intervention and prevention in hereditary breast cancer. Monogr Natl Cancer Inst. 17:1995;99-102.
52. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 339:1998;424-428.
53. Narod S.A., Goldgar D., Cannon-Albright L., et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer. 64:1995;394-398.
54. Giardiello F.M., Brensinger J.D., Petersen G.M., et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med. 36:1997;823-827.
55. Li F.P. Translational research on hereditary colon, breast, and ovarian cancers. Monogr Natl Cancer Inst. 17:1995;1-4.
56. NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research Task Force on Genetic Testing. Promoting Safe and Effective Genetic Testing in the United States, http://ww2.med.jhu.edu/tfgtelsi/promoting.
57. Clayton E.W., Steinberg K.K., Khoury M.J., et al. Informed consent for genetic research on stored tissue samples. JAMA. 274:1995;1786-1792.
58. Andrews L.B., Fullarton J.E., Holtzman N.A., et al. Assessing genetic risks. Implications for health and social policy. 1994;Institute of Medicine, Washington, DC.
59. Lerman C., Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med. 154:1994;609-616.
60. Lerman C., Narod S., Schulman K., et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 275:1996;1885-1892.
61. Offit K., Brown K. Quantitating familial cancer risk a resource for clinical oncologists . J Clin Oncol. 12:1994;1724-1736.
62. Geller G., Botkin J.R., Green M.J., et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA. 277:1997;1467-1474.
63. Rothenberg K.H. Genetic discrimination and health insurance a call for legislative action . J Am Med Womens Assoc. 52:1997;43-44.
64. Hayflick S.J., Eiff M.P. Role of primary care providers in the delivery of genetics services. Community Genetics. 1:1998;18-22.